Wuxi Biologics (cayman) Inc. · HKEX:2269
Wuxi Biologics (cayman) — WuXi Biologics — 42nd Annual J.P. Morgan Healthcare Conference (2024)
35 slides from Wuxi Biologics (cayman)'s conference presentation, 2024
Slide 1: Global Premier CRDMO: Enabling Global Partners and Delivering Sustainable High Growth
Global Premier CRDMO: Enabling Global Partners and Delivering Sustainable High Growth Chris Chen PhD 42nd Annual J.P. Morgan Healthcare Conference Stock Code: 2269.HK
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe
Slide 3: Contents
CONTENTS Microbial Business to be Business Update 02 01 Another Growth Driver State-of-the-art Seven Success Factors also Technologies Lead to 03 Proven on XDC 04 Future Success ESG as an Important Component 05 of Business Strategy 06 Summary 3
Slide 4: Business Update
Business Update 01
Slide 5: Top Global Bioprocessing Trends in 2023: Betting on the Right Trends
Top Global Bioprocessing Trends in 2023: Betting on the Right Trends CMO on Single-use technology Offshoring the Rise The growth in contract Single-use technologies Globalization of manufacturing facilities are accelerating the biomanufacturing and means that biopharma replacement of stainless offsh
Slide 6: New Projects Rebound from the Bottom in Q1 2023: 2023 Record High
New Projects Rebound from the Bottom in Q1 2023: 2023 is Now Record High of New Non-COVID Projects No. of Newly Added Integrated Projects 2023 New Project Region Mix 138 (1) 136 132 127 71 132 ROW (2) 124 6% 103 85 China 15 25% North 61 58 57 59 America 38 46 55% Europe 8 14% 2017 2018 2019 2020 202
Slide 7: "Win-the-Molecule" Strategy: Another Driver to Expand Pipeline
“Win-the-Molecule” Strategy: Another Driver to Expand Pipeline and Deliver Additional Near-term Growth 2018 2019 2020 2021 2022 2023 • 9 phase III and Commercial “Win-the-Molecule” projects: record high, 9 69 significantly higher than our original expectation of 5 • Total 69 projects at different st
Slide 8: New Projects Exceeded Expectations: Business Resilience Despite Headwinds
New Projects Exceeded Expectations: Demonstrate Business Resilience Despite Headwinds WuXiBodyTM OMT Platform ADC Platform SDArBodYTM • Continue to gain market share for both “Follow and Win the Molecule” • Despite headwinds, newly-added projects “R” Multiple-Platform Discovery Engines reached all t
Slide 9: CMO Continues with Strong Momentum: No. of PPQs
CMO Continues with Strong Momentum as Shown by Leading Indicators: No. of PPQs DS PPQ • Robust growth in drug 34%+ 52% substance (DS) and drug 9+ 1 product (DP) PPQs, in line with our CMO project 34 38+ 23 increase: will add more in 9 14 4 2024 2019 2020 2021 2022 2023 2024 China EU • Growing number
Slide 10: Ireland Ramp-up Ahead of Schedule: Expect to Break Even in 2024
Ireland Ramp-up Ahead of Schedule: Expect to Break Even in 2024 • Ireland site completed construction with record speed and received the 2023 Facility of the Year Award (FOYA) in the Operations category from ISPE • GMP runs at both facilities are proceeding as expected: the first PPQ batch was succe
Slide 11: Explosive Growth of Commercial Projects in the Near Term
Explosive Growth of Commercial Projects in the Near Term Seven manufacturing projects Ten manufacturing projects that Eight manufacturing projects that could potentially generate could potentially generate that could potentially generate US$200 mm+ peak revenue per US$100-200 mm peak revenue US$50-1
Slide 12: QUALITY is Our Competitive Advantage
QUALITY is Our Competitive Advantage Number of Regulatory Inspections Completed: 32 (1) Number of License Approvals: 45 (60 by Facility) (2) Facility MFG1 MFG2F MFG2P MFG4 MFG5 DP1 DP4 MFG3(CB) MFG3 Agency 32 WBP XXX WBP XXX WBP XXX WBP XXX WBP XXX/ 1 FDA (6) WBP XXX WBP XXX WBP XXX WBP XXX WBP XXX
Slide 13: Leading Indicators of Quality: Favorable Trends During Client Audits
Leading Indicators of Quality/Regulatory Inspections: Continue to See Favorable Trends During Client Audits Major Findings per Audit Critical+ Major Findings 90 Total of Client Audits 80 Major finding Rate 70 65 65 64 56 58 56 60 55 55 55 50 48 50 50 1.71 45 41 38 36 1.34 37 36 40 35 29 27 29 29 28
Slide 14: Microbial Business to be Another Growth Driver
Microbial Business to be Another Growth Driver 02
Slide 15: Thriving Growth in Microbial Business
Thriving Growth in Microbial Business End-to-end One-stop Shop from DNA to Regulatory Filling Strain Analytical DS GMP DP GMP Analytical Process Development Development Manufacturing Manufacturing Validation Validation DS Process Formulation DP Process QC Release Process Regulatory Development Devel
Slide 16: Strong "D" and Expansion for "M"
Strong “D” and Expansion for “M” D Strong development capabilities M Proprietary Expression Systems Microbial Process Development Commercial Projects Microbial Host & Plasmid Innovations Comprehensive Tool-box, Enriched Experience High throughput process development technology FOT host Stable expres
Slide 17: Seven Success Factors also Proven on XDC
Seven Success Factors also Proven on XDC 03
Slide 18: Seven Keys for Future Success: Sustainable High Growth
SEVEN Keys for Future Success: Sustainable High Growth Technology Execution Quality People Speed Flexibility Strategy BETTER FASTER CHEAPER 18
Slide 19: Global Leading ADC and Bioconjugate CRDMO
Global Leading ADC and Bioconjugate CRDMO Global Market Share Continues to Increase No.1 Globally *Calculated by revenue By integrated project number 9.8% No.2 Globally By 2022 revenue 4.6% No.1 in China 1.8% By 2022 revenue 2020 2021 2022 Conjugation Commercial Antibody Discovery CMC Development IN
Slide 20: "Enable-Follow-Win" Strategy Builds Robust Project Base
“Enable-Follow-Win” Strategy Builds Robust Project Base Number of Ongoing Projects Enable “R” 350 Discovery(1) 30 ADC Candidates progressed from discovery to CMC(3) 67 Preclinical(2) Follow 27 Phase I Nearly All our customers for bioconjugate discovery or CMC projects, “D” 43 ongoing advancing their
Slide 21: Seven Success Factors also Proven on XDC
Seven Success Factors also Proven on XDC XDC is the one and only pure-play ADC CRDMO player A Fast Growing Customer Base… offering end-to-end services 167 Successful execution: powerful Platform Cutting Timeline by Half: From DNA to IND in < 15 months 115 State-of-the-art technologies underpin futur
Slide 22: State-of-the-art Technologies Lead to Future Success
State-of-the-art Technologies Lead to 04 Future Success
Slide 23: WuXi Bio's Proprietary Clinical Stage Anti-CD3 mAb
WuXi Bio’s Proprietary Clinical Stage Anti-CD3 mAb Empowers Discovery of Best-in-Class T Cell Engagers (TCEs) WuXi CD3 Platform Highlights Potent Tumor Killing with Minimal Cytokine Release • 3 TCEs in clinical stage (Ph1 clinical trials) • Cynomolgus monkey cross-reactive CD3 binder • Unique epitop
Slide 24: WuXiUI Performance and Strategic Applications to Commercial Manufacturing
WuXiUITM Performance and Strategic Applications to Biologics Commercial Manufacturing Productivity Comparison WuXiUITM Ultra-Intensified FB Bioprocessing Strategy WuXiUITM vs. TFB Titer Folds of Increase 30 516% 6 503% • 3~6 folds of TFB productivity with WuXiUITM 452% Folds of Increase 25 188% 5 33
Slide 25: Disposable Bioreactors CAN Deliver Lower COGS than Stainless Steel
Disposable Bioreactors CAN Deliver Lower COGS than Traditional Stainless Steel VS VS Disposable 30%+ more expensive Disposable ~20% cheaper 2,000L Single-use Bioreactor 12,000L Traditional Stainless Steel Bioreactor 12,000L Traditional Stainless Steel Bioreactor 6x2,000L Single-use Bioreactor VS VS
Slide 26: ESG as an Important Component of Business Strategy
ESG as an Important Component of 05 Business Strategy
Slide 27: ESG Performance Recognized as Industry Leader
ESG Performance Recognized as Industry Leader Dow Jones Sustainability World Index MSCI AAA Dow Jones Sustainability Emerging Markets Index ESG Rating of 2023 • The highest rating on MSCI’s AAA (Leaders) • Ranked No.1 in its sector and identified as a to CCC (Laggards) global sustainability leader •
Slide 28: ESG Performance Recognized as Industry Leader
ESG Performance Recognized as Industry Leader • Ranked in top 1% of 100,000+ companies This is really fantastic news! • Outstanding performance across all areas: So excited to hear WuXi Bio is Environment, Labor & Human Rights, Ethics, doing an excellent job with and Sustainable Procurement EcoVadis
Slide 29: Integrated Strategy to Tackle Climate Change
Integrated Strategy to Tackle Climate Change Advocate Energy Saving Initiatives Across Global Sites Five Efforts & Committed to Carbon Targets Approaches Progress SBTi Measure 50% 21% Mid-term: Reduce GHG Avoid emissions intensity by GHG emission intensity 50% by 2030 YOY decrease in 2022 Reduce Sub
Slide 30: Our Commitment to A More Sustainable Business
Our Commitment to A More Sustainable Business SBTi ISO 27001 ISO Information Security Management ISO 45001 Committed to SBTi in 2023 Occupational Health and Safety A new milestone towards net-zero ISO 14001 Environmental Management ISO 14064 GHG Emissions Verification UNGC TCFD A TCFD Supporter in 2
Slide 31: Summary
Summary 06
Slide 32: CRDMO: Three Growth Curves Drive Sustainable Long-term Growth
CRDMO: Three Growth Curves Drive Sustainable Long-term Growth Three Long-Term Growth Curves R+D+M D+M D 2019 2013 2017 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 32
Slide 33: Proven CRDMO Business Model Continues to Deliver Sustainable Growth
Proven CRDMO Business Model Continues to Deliver Sustainable Growth C R • D • Cell Line Engineering M O Contract Target Selection • DS GMP Manufacturing One partner Services • Reagent/Protein Generation & Assay Development • Assay Development • DP GMP Manufacturing with • Antibody Generation • Proce
Slide 34: Outlook & Summary
Outlook & Summary Highlights in 2023 Solid Growth in 2024 and beyond Biotech funding slowdown and CMO revenue deferral made 2023 a Continue to gain market share in challenging year, though the R, D and M, especially in “D” temporary impacts did not affect through follow the molecule the Company’s fu
Slide 35: WuXi Bio Vision
WuXi Bio Vision “Every drug can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry 35 35
WuXi Biologics — 42nd Annual J.P. Morgan Healthcare Conference (2024) on 6ix